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chemia lasting 1.25 (n ~ 18), 2.5 (n = 20), 5 (n = 9), or 10 (n ~ 161 min, or
multiple episodes cumulating in 10 (2 x 5 min, n = 17) or 20 (4 x 5 min,
n = 13 or 2 x 10 min, n = 14) min of preconditioning ischemia time, all
followed by 5 min of reperfusion. Control rats (n ~ 22) were not precondi-
tioned. In separate groups, glycogen was determined before whereas infarct
size was determined after prolonged ischemia (45 min) and reperfusion (120
min). Myocardial glycogen levels and infarct size are shown as a function of
preconditioning ischemia time.
Protocol I, dogs received 45-min episodes of preconditioning ischemia (PC:
n = 7) or a comparable control period In ~ 9) before sustained CO; Proto-
col II was identical except polymyxin-B (PMX: 50 mg/kg) was administered
throughout the PC regimen (n = 6) or control period (n = 6). Blood flow to
the ischemic subendocardium was assessed during sustained CO by injec-
tion of rauiolabeled microspheres, and area of necrosis (AN) was delineated
by tetrazolium staining and expressed as a % of the area at risk of infarction
(ARI.
PC G + PC AD G + AD CP G+ CP CG G + CG
t P:5 0.05: one-way ANOVA and SNK multiple range test
Endo Flow (mllminlg) ANIAR (%)
Protocol I: Control 006 ± 0.02 19 ± 3
PC 0.09 ± 003 6 ± 2"
Protocol II: Control + PMX 001 ± 001 29 ± 5
PC + PMX 0.02 ± 001 10 ± 3\
" P < 0.01 vs Control: \ p < 0.01 vs Control + PMX
Michel Ovize, Jean F Aupetlt, Gilles Rioufol, Joseph Loufoua, Xavier Andre-Foust,
Yves Minaire. Hopital Cardiologique, Lyon, France; University Claude Bernard, Lyon,
France
Preconditioning (PC) prevents ventricular fibrillation (VF) in the rat heart. We
sought to determine whether this protective effect might: (11 apply to the pig
heart, (2) be related to modifications of electrophysiologic parameters. Forty-
eight anesthetized pigs underwent 40 min of LAD coronary artery occlusion
(CO) followed by 2 hours of reperfusion (R) Prior to this, PC hearts received
10 min of CO and 10 min of R. Area at risk and infarct size were measured by
injection of blue dye and triphenyltetrazolium staining, respectively. Duration
of subepicardial monophasic action potential (MAPD) and VF threshold were
measured at different time points of the experiment. As expected, infarct
size was significantly reduced in PC hearts, averaging 6 ± 4%' of the risk
region versus 28 ± 4% in controls (* p < 0.01). But, incidence of VF was
not reduced in the PC group: 69% vs 63% in the control group (p = NSI.
Furthermore, time to VF during the 40 minute CO was significantly shorter
in PC than in control hearts: 7 ± 2 min' vs 18 ± 2 min 1* p < 0.01). This was
associated with a significantly lower VF threshold and shortening of MAPD
in PC hearts at the onset of the sustained CO. At 3 min of ischemia, VF
threshold averaged 2.3 ± 1.7 mAIO in PC vs 4.1 ± 2.4 mA in controls (* p
< 0.01 vs control). MAPD averaged 197 ± 4 ms' in PC hearts versus 214 ±
4 ms in controls 1* p < 0.05). This suggests that preconditioning does not
prevent but accelerates ventricular fibrillation in pig hearts via a decrease
of the fibrillation threshold and a shortening of monophasic action potential
during the first minutes of the sustained ischemia.
Protocol I confirmed the expected reduction in infarct size in precondi-
tioned dogs vs. controls. Protocol II revealed that all PMX-treated dogs were
rendered profoundly ischemic during CO. Nonetheless, treatment with PMX
did not attenuate the reduction in infarct size achieved with preconditioning.
Thus, the PKC inhibitor polymyxin-B may exacerbate ischemia during CO:
this may contribute to the previously reported "increase" in infarct size in
preconditioned rabbits treated with this agent. Polymyxin-B did not, however,
block the cardioprotective effects of preconditioning in this canine model.
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1706-41 Preconditioning Shortens Action Potential Duration
and Lowers Ventricular Fibrillation Threshold in Pig
Hearts
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In addition, infarct size reduction correlated with glycogen depletion be-
fore prolonged ischemia (r = 0.98; 19 P < 0.001). Thus, increasing precondi-
tioning ischemia time results in progressive myocardial glycogen depletion
and infarct size reduction, reaching a maximal effect when the precondition-
ing ischemia time is :0:5 min. This maximal effect may be due to marked
depletion of myocardial glycogen stores before prolonged ischemia.
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The anti-infarct effect of ischemic preconditioning (PC) is partly due to adeno-
sine receptor-mediated opening of KATP channels. PC-mediated protection
may be potentiated by exogenous infusion of adenosine receptor agonists.
To test this hypothesis, pentobarbital anesthetized rabbits (n = 8/group) un-
derwent two cycles of 5 min regional ischemia and 5 min coronary reperfu-
sion (REP; i.e., PC) followed by 30 min ischemia and 3 h REP Rabbits received
either adenosine (AD; 0.01 mg/min); cyclopentyladenosine (CP; Al recep-
tor agonist; 0.001 mg/minl or CGS 21680 (CG; A2 receptor agonist; 001
mg/min), i. v. for 65 min starting 5 min before onset of REP KATP channels
were blocked with i.v. glibenclamide (G; 0.15 mglkg) 10 min before PC in the
absence or presence of AD, CP or CG. Infarct and risk (R; cm3) volume was
assessed with tetrazolium and microsphere autoradiography. Infarct size (IS)
was normalized to R. IS in absolute controls (i.e., no PC) was 51 ± 6% (mean
±SEMI
R 1.6± 1 1.8±0.2 1.6±0.2 1.4±0.1 1.9±0.1 1.4±0.3 2.0±0.2 1.2±0.1
IS 19±2 39±7t 27±7 37±6t 12± 1 44±9t 22±3 50±5t
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1706-21 Adenosine-mediated Myocardial Protection During
Preconditioning is Abolished by KATP Channel
Blockade in Rabbits
John G. Kingma Jr., Mette Hazenberg, Denis Simard, Jacques R. Rouleau. Laval
University, Quebec, Canada
Cardiodynamics were similar for the treatment groups; but heart rate-
blood pressure product was lower (p ::: 0.05) during CP infusion. Conclu-
sions: 1) PC markedly reduced IS; 2) PC-mediated protection was not po-
tentiated with exogenous AD, CP or CG; and 3) G abolished PC-mediated
protection withouVwith exogenous AD, CP or CG. These data indicate that
adenosine receptor activation and opening of KATP channels are involved in
Pc.
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The Protein Kinase C Inhibitor Polymyxin-B does not
Block Preconditioning-induced Cardioprotection in
the Canine Model
Karin Przyklenk, Robert A. Kloner. Heart Institute, Hospital of the Good Samaritan, Los
Angeles, CA; University ofSouthern California, Los Angeles, CA
In the rabbit model, administration of protein kinase C IPKCI inhibitors such
as polymyxin-B have been reported to attenuate the reduction in infarct size
achieved with ischemic preconditioning. Activation of PKC has therefore
been proposed to playa crucial role in the mechanism by which precon-
ditioning protects the heart from subsequent sustained coronary occlusion
(CO). However, the possible confounding effects of PKC inhibition on my-
ocardial blood flow were not assessed in these studies. We addressed this
issue in 28 dogs subjected to 1 h of sustained CO and 4-5 h of reperfusion. In
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1706-51 Calcitonin Gene-related Peptide Improves Recovery
from Reversible Myocardial Ischemia
Ravi N. Samy, Scott C. Silvestry, B. Zane Atkins, James W. Davis, R. Eric Lilly, David
C. Sabiston, Jr., Donald D. Glower. Duke University, Durham, NC
Calcitonin gene-related peptide (CGRP) has been found to have inotropic
properties and a short half-life. CGRP has been demonstrated to reduce is-
chemic injury in tissue flaps as well as to increase coronary artery flow, while
other available inotropes have been shown to impair recovery from myocar-
dial ischemia. Yet, a therapeutic role for CGRP in myocardial ischemia has
not been defined. Therefore, CGRP was compared to placebo in nine chron-
ically instrumented conscious dogs who underwent two 15 minute left an-
terior descending coronary artery occlusions separated by at least 24 hours
of reperfusion. Left ventricular transmural pressure and myocardial segment
length were measured at control and during reperfusion. Either CGRP (0.07
Ilg/kglmin) or saline placebo was randomly chosen and continuously infused
from 45 to 105 minutes of reperfusion. The alternative infusion was given
during the second study. Regional function was assessed using preload re-
cruitable work area (PRWA), a load-insensitive measure of regional myocar-
dial performance. PRWA was calculated as the area beneath the linear stroke
work vs. end-diastolic length relationship. Data are mean PRWA (% of con-
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In conclusion, 6 months of treatment with carvedilol in patients with is-
chemic heart failure resulted in improved ejection fraction and reduced LV
chamber dimensions. However, there were no detectable changes in maxi-
mal or submaximal exercise performance or in NYHA class.
*p < 001; t p ~ 004; all others NS. EF ~ ejection fraction, LV = left ventricular, EDD ~
end-diastolic dimension, ESD = end-systolic dimension
10:45
1707-21 Effects of Carvedilol on Left Ventricular Function and
Exercise Performance in Patients with Heart Failure
of Ischemic Etiology
Stephen MacMahon, Robert Doughty, Norman Sharpe, ANZ Heart Failure
Research Collaborative Group. University ofAuckland, Auckland, New Zealand
Results from several small trials in patients with heart failure of predom-
inantly idiopathic etiology suggest that beta-blocker therapy may improve
ventricular function, but the effects on exercise performance remain less
certain. To determine the effects of such treatment in patients with heart
failure of ischemic etiology, patients with this condition and ejection fraction
(EF) <45% were randomized to treatment with carvedilol (12.5-50 mg/day)
or placebo. Prior to randomization, 444 patients entered a 2-3 week run-in
phase on open label, low-dose carvedilol (6.25-12.5 mg/day). 415 patients
(93%) were randomized. Primary outcome variables were radionuclide mea-
surements of EF and measurements of treadmill exercise duration (TED) us-
ing a modified Naughton protocol. Secondary outcomes included leftventric-
ular chamber dimensions measured by M-mode echocardiography, submax-
imal exercise performance assessed from 6 minute walk distance (6 MWO)
and NYHA functional class. After 6 months, resting heart rate was reduced by
7.1 bpm, and blood pressure was reduced by 5.1 /4.5 mmHg in the carvedilol
group compared to the placebo group. Results for the main outcomes are
shown below as differences between carvedilol and placebo groups after 6
months of follow-up.
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1707-31 CISIS Left Ventricular Function Sub-study: Analysis
of Predictive Factors of Initial Improvement and
Prognostic Value
24 Hours
79 ± 7
*108 ± 15
94 ± 10
*118 ± 12
8 Hours
82 ± 8
*115 ± 9
3 Hours
89 ± 7
*155 ± 22
90 Min
* p < 0.05 vs. placebo
Hong Han. Barbara Braeker, Stefan Neubauer, Georg Ertl. Department ofMedicine,
Wiirzburg University, FRG
Using specific Endothelin-l (ET-1) antagonists B0123 and B061 0, we tested
whether endogenous ET-1 contributes to ischemia/reperfusion injury in iso-
lated, Langendorff-perfused rat hearts. B0123 (7 J.Lg/min) and B0610 (1.75
/Lg/min) did not affect mechanical function or coronary flow and shifted the
dose-response curve for ET-1 significantly to the right. Isovolumic rat hearts
were pre-treated with B0123, B0610 or saline for 10 min, and were sub-
jected to 30 min ischemia followed by reperfusion. At 15 min ischemia,
the increase of left ventricular resting pressure (mmHgl was significantly re-
duced by BO 123(17 ± 3*; n ~ 11) and B0610(17 ± 3*; n = 12) compared to
saline (45 ± 7; n = 12). During reperfusion, recovery of left ventricular devel-
oped pressure (mmHg) was improved with B0123 123 ± 7*) and B061 0 (20
± 3*) compared to saline (10 ± 3). In hearts pre-treated with B0610, high-
energy phosphate metabolism was continuously recorded with 31P-NMR
spectroscopy (n Bruker NMR System). ATP content (% of control) at 30 min
ischemia was higher with B0610 (20 ± 3*; n = 11) compared to saline (5 ±
2; n ~ 8), and creatine phosphate recovery (% of control) was improved with
B0610 during reperfusion (76 ± 7* vs 54 ± 6 with saline). Thus, endogenous
ET-1 contributes to ischemia/reperfusion injury. Specific ET-1 antagonists at-
tenuate functional and metabolic consequences of ischemia/reperfusion in-
jury without affecting pre-ischemic workload.
*p < 0.05 vs. saline.
Despite a short half-life of less than 30 minutes, CGRP caused a signif-
icantly more rapid return of cardiac function from ischemia than placebo
throughout the entire 24 hours of reperfusion. These results suggest that
CGRP may improve recovery from reversible myocardial ischemia and may
have unique properties as an intravenous inotrope in an intensive care unit
setting because it does not appear to impair recovery from acute myocardial
ischemia.
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Endothelin-1 Receptor Antagonists SQ123 and
BQ610 Delay Ischemic Contracture, Preserve
High-Energy Phosphate Metabolism and Improve
Systolic Function During Ischemia/Reperfusion
Placebo
CGRP
trol) ± SEM for the 9 dogs.
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1707-1 I Short-term ACE-Inhibition and Onset and
Progression of Congestive Heart Failure in Patients
with Acute Myocardial Infarction
Claudio Borghi, Ettore Ambrosioni, Bruno Magnani, SMILE Investigators.
University ofBologna, Bologna, Italy
Anterior acute myocardial infarction (AMI) is often complicated by clinical
signs of CHI' We report the data of 1146 patients with anterior AM.1. with-
out previous history or clinical signs of CHF on admission and enrolled un-
der the SM/LE study. Patients were randomly allocated to a 6-week double-
blind treatment with placebo (P) or zofenopril (ZI and then followed-up for 1
year. Baseline demographic characteristics were similar in Z and Pgroup who
were comparable for blood pressure, ECG pattern, peak CPK, and concomi-
tant drug treatment. After 6 weeks the cumulative occurrence of CHF was
not different in Z and P groups (13.3% vs 13.9%; P = 0.234). Clinical signs of
mild to moderate CHF were present in 11.7% ofthe Z population and 10.2%
of the P group (P = 0.178) whereas severe refractory CHF occurred signif-
icantly less in Z (1.6%) compared to P (3.6%) patients (RR = 2.3: C.1. 95%
1-3.3: p = 0.0328). After 1 year the overall occurrence of CHF was 14.8% in
P and 15.4% in Z treated patients. NYHA class I was more common among
Z treated patients (8.2% vs 1.5%; P = 0.021) whereas the percentage of pa-
tients in NYHA class IV was higher in P treated patients (24.3% vs 11.0%;
p = 0.001). In conclusion the early and long-term development and progres-
sion of CHF can be prevented by short-term administration of zofenopril in
patients with acute myocardial infarction.
Philippe Lechat, Herve Lardoux, Jean-Pierre Boissel, Serge Witchitz, Martin Hetzel,
Luigi Ciampricotti, Eric Chanton, Christian Mesenge, Patrice Jaillon, CIBIS
Investigators. ClBIS Coordinating Center, Pitie-5alpetr;';'re Hospital, Paris, France
During the Cardiac Insufficiency Bisoprolol Study (CiBIS) which evaluated
beta-blockade IBB) effects on mortality in 641 patients (pts) with heart fail-
ure (mean follow up: 1.9 ± 0.8 years, SO), we studied the determinants of
BB induced improvement of left ventricular function (LVFL the mechanism
of which remains unclear. Echocardiographic assessment of LVF was per-
formed at baseline (BL) in all patients and in a subgroup of 164 patients 183
on B, 81 on P) still alive 5 months after inclusion. All patients received a back-
ground diuretic and vasodilator therapy and were blindly randomized either
to placebo (P) or to bisoprolol (B). Among these 164 pts, a similar proportion
in both groups presented with left bundle branch block (23 on P. 22 on B, NS)
or chronic atrial fibrillation (15 on P. 10 on B, NS). According to all recorded
parameters at baseline, this subgroup of pts was representative of the entire
CIBIS population. Results (means ± SD):
EDD Icm) ESD (em) FS(%I
BL P 68 ± 0.9 5.7 ± 0.9 16.8 ± 46
B 69 ± 0.8 5.8 ± 08 155 ± 5.0
5M P 6.8 ± 1.0 57 ± 1.0 16.8 ± 5.8
B 6.7 ± 0.9 5.4± 1* 20.1 ± 7.0**
EDD ~ end diastolic diameter; ESD ~ end systolic diameter; FS ~ fractional Shortening;
* p ~ 0.07; •• p = 0.001
LVFS significantly improved on Bat 5 months compared to P (LVFS varia-
tion was: -0.04 ± 5.5% with P and +4.6 ± 6.5% with B, p < 0.001). Such im-
provement was similar in ischemic and non ischemic pts. It was uncorrelated
to other BL parameters and to B induced bradycardia (-18 ± 12 beats/min at
5 ML but it was significantly correlated with survival after the initial 5 month
period (Cox model, 12 patients died on P. 7 on B, p = 0.01).
We conclude that echocardiographic LVFS improvement on B is an inde-
pendent marker of BB action in heart failure appears uncorrelated to baseline
parameters but is associated with a better prognosis.
